A double-blind, randomized, active- and placebo-controlled four-way crossover trial to evaluate the abuse potential of IV CR845 in non-dependent, recreational polydrug users with lifetime and recent hallucinogenic drug use

Trial Profile

A double-blind, randomized, active- and placebo-controlled four-way crossover trial to evaluate the abuse potential of IV CR845 in non-dependent, recreational polydrug users with lifetime and recent hallucinogenic drug use

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Difelikefalin (Primary) ; Pentazocine
  • Indications Pain
  • Focus Adverse reactions
  • Sponsors Cara Therapeutics
  • Most Recent Events

    • 03 Nov 2016 According to a Cara Therapeutics media release, the data from this trial presented at PAINWeek and the Orthopaedic Trauma Association 2016 Annual Meeting
    • 31 May 2016 According to a Cara Therapeutics media release, the results from this trial will be presented at the International Conference on Opioids.
    • 10 Mar 2016 According to a Cara Therapeutics media release, data from this study was presented at the American Academy of Pain Medicine's 32nd Annual Meeting in February 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top